Oppenheimer assumed coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $32.00 ...

Fintel reports that on January 30, 2025, Oppenheimer initiated coverage of Alumis (NasdaqGS:ALMS) with a Outperform ...

Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is still one of the most lethal cancers and does not yet have an effective therapy. There is an urgent need to identify ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...

Alumis (ALMS) stock gains as Oppenheimer initiates coverage with an Outperform recommendation, citing a valuation disconnect. Read more here.

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering ...

Sara Klein was promoted to chief legal officer at Alumis, a clinical stage biopharmaceutical company, according to a Tuesday announcement.

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

IPG Photonics Corporation (Nasdaq: IPGP) will release its fourth quarter 2024 financial results before the market opens on Tuesday, February 11, 2025. The Company will hold a conference call to review ...

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have ...